Top Page
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
(Sydney:RMD)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) vs. iShares MSCI Australia ETF (EWA)
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Business Overview & Revenue Model
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Earnings Call Summary
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.02B | 5.15B | 4.69B | 4.22B | 3.58B | 3.20B |
| Gross Profit | 2.94B | 3.05B | 2.66B | 2.36B | 2.02B | 1.84B |
| EBITDA | 1.71B | 1.92B | 1.53B | 1.36B | 1.18B | 1.10B |
| Net Income | 1.31B | 1.40B | 1.02B | 897.56M | 779.44M | 474.50M |
Balance Sheet | ||||||
| Total Assets | 7.57B | 8.17B | 6.87B | 6.75B | 5.10B | 4.73B |
| Cash, Cash Equivalents and Short-Term Investments | 932.71M | 1.21B | 238.36M | 227.89M | 273.71M | 295.28M |
| Total Debt | 839.77M | 851.81M | 873.93M | 1.58B | 917.55M | 793.72M |
| Total Liabilities | 2.02B | 2.21B | 2.01B | 2.62B | 1.74B | 1.84B |
| Stockholders Equity | 5.55B | 5.97B | 4.86B | 4.13B | 3.36B | 2.89B |
Cash Flow | ||||||
| Free Cash Flow | 1.56B | 1.65B | 1.29B | 559.30M | 195.11M | 619.89M |
| Operating Cash Flow | 1.65B | 1.75B | 1.40B | 693.30M | 351.15M | 736.72M |
| Investing Cash Flow | -112.84M | -200.04M | -269.78M | -1.16B | -229.92M | -158.46M |
| Financing Cash Flow | -835.65M | -606.25M | -1.12B | 422.87M | -128.36M | -764.63M |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Technical Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Risk Analysis
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | AU$64.26B | 30.70 | 26.44% | 0.76% | 11.26% | 39.47% | |
51 Neutral | $7.83B | -0.15 | -40.10% | 2.29% | 21.46% | -2.01% | |
| ― | €18.09B | ― | -1.63% | ― | ― | ― | |
| ― | $12.79B | 53.48 | 20.11% | 1.35% | ― | ― | |
| ― | $20.53B | 262.41 | 50.70% | 0.15% | ― | ― | |
| ― | $5.73B | 1,132.50 | 0.52% | 2.02% | ― | ― | |
73 Outperform | AU$11.78B | 22.55 | 6.32% | 4.49% | 9.63% | -0.37% |
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh Corporate Events
ResMed Inc has filed a Form 144 for the proposed sale of 3,000 common shares, valued at approximately $845,700, on the NYSE. The shares are being sold by Brett Sandercock, an officer of the company, and were acquired through restricted stock vesting and option grants. This sale reflects a routine transaction and is not expected to significantly impact the company’s operations or market positioning.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$41.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s CEO, Michael J. Farrell, executed transactions involving the company’s common stock under a pre-established Rule 10b5-1 plan. This plan allows for the planned sale or purchase of securities, providing a structured approach to managing stock transactions. The transactions involved the acquisition and subsequent sale of 8,009 shares, reflecting strategic financial management by the company’s leadership. These actions are part of a broader strategy to optimize stock holdings and align with corporate governance practices, potentially impacting stakeholder perceptions and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has announced a proposed sale of securities under Rule 144, with Michael J. Farrell, an officer and director of the company, planning to sell 8,009 shares of common stock. The sale is expected to occur on July 7, 2025, with the aggregate market value of the shares estimated at approximately $2,056,075.99. This transaction follows previous sales by Farrell in April and May 2025, which generated gross proceeds of over $3.6 million. The announcement may impact stakeholder perceptions and market dynamics, given Farrell’s significant role within the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported changes in his beneficial ownership of the company’s stock, as per a transaction plan under Rule 10b5-1. The transactions involved acquiring and disposing of shares, reflecting strategic financial management and adherence to regulatory compliance, potentially impacting investor perceptions and market dynamics.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc., a company involved in the healthcare industry, focuses on the development and manufacturing of equipment related to sleep disorders and respiratory care. The recent filing indicates a transaction involving the sale of common stock by Michael J. Rider, Global General Counsel and Secretary, under a pre-established Rule 10b5-1 plan. This transaction reflects changes in beneficial ownership and may have implications for the company’s stock market activities.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc announced an increase in the number of CHESS Depositary Interests (CDIs) issued over quoted securities, with a net addition of 1,288,180 CDIs in June 2025. This change is attributed to net transfers between CDIs and common stock, as well as activities related to stock options and employee stock plans. The adjustments reflect the company’s ongoing efforts to manage its securities and optimize its capital structure, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has announced a proposed sale of securities under Rule 144, with a director, Peter C. Farrell, planning to sell 945 common shares through Merrill Lynch. This move follows previous sales of 6,000 shares over the past three months, indicating a continued divestment by the director. The sale is scheduled for July 2, 2025, and could potentially impact the company’s stock market performance and investor sentiment, given the significant role of the director in the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc. has announced that it will release its financial and operational results for the fourth quarter of fiscal year 2025 on July 31, 2025, after the New York Stock Exchange closes. The announcement includes a webcast for discussing the results, which may impact stakeholders by providing insights into the company’s performance and strategic direction.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has filed a notice of proposed sale of securities under Rule 144, indicating that Michael J. Rider, an officer of the company, plans to sell 66 shares of common stock. This filing is part of a series of transactions, with previous sales occurring in April and June 2025, reflecting ongoing stock management by company insiders. The sales are executed through Fidelity Brokerage Services LLC, and the transactions are part of restricted stock vesting, highlighting routine financial activities within the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has reported a change in beneficial ownership as per a transaction conducted under a Rule 10b5-1 plan. Peter C. Farrell, the Chairman Emeritus, disposed of 2,000 shares of ResMed common stock at a price of $247.32 per share, leaving him with a total of 69,218 shares. This transaction reflects ongoing strategic financial management within the company and may have implications for stakeholders regarding the company’s stock performance and executive shareholding patterns.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc has filed a Form 144 indicating a proposed sale of securities under Rule 144 of the Securities Act of 1933. The filing involves the sale of 2,000 common shares by Peter C. Farrell, a director of the company, with an aggregate market value of $500,000. The transaction reflects insider activity and may have implications for the company’s stock performance and investor perceptions.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has announced a net decrease in the number of CHESS Depositary Interests (CDIs) issued over quoted securities for May 2025, with a reduction of 1,750,140 CDIs compared to the previous month. This change is attributed to net transfers of securities between CDIs and common stock held on the NYSE. Additionally, there was a decrease in the total number of securities over which CDIs have not been issued, due to transfers between CDIs quoted on ASX and new share issues on the NYSE related to stock options and employee plans, as well as share repurchases.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc.’s Chief Financial Officer, Brett Sandercock, reported a transaction involving the sale of 1,000 shares of ResMed common stock under a pre-established Rule 10b5-1 trading plan. This transaction, executed on June 2, 2025, reflects the CFO’s adherence to regulatory compliance while managing personal stock holdings. Such transactions are part of routine financial management and may not directly impact the company’s operational strategies or market position.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed a Form 144 notice indicating the proposed sale of securities by Michael J. Rider, an officer of the company. The filing outlines the sale of 41 common shares with an aggregate market value of $9,994.98, scheduled for June 2, 2025. This transaction follows previous sales by Rider in March and April 2025, reflecting ongoing personal financial management activities. The announcement does not indicate any adverse information regarding ResMed’s current or future operations, suggesting stability in the company’s market position.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has filed a notice of proposed sale of securities under Rule 144, indicating that Brett Sandercock, an officer of the company, plans to sell 1,000 shares of common stock. The sale is scheduled for June 2, 2025, with an aggregate market value of $243,780. This move follows previous sales by Sandercock in March and April 2025, reflecting ongoing transactions that may impact the company’s stock liquidity and stakeholder interests.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has filed a Specialized Disclosure Report, Form SD, in compliance with the Securities Exchange Act Rule 13p-1 for the reporting period of January 1 to December 31, 2024. The report addresses the company’s conflict minerals disclosure, detailing the reasonable country of origin inquiry process and its outcomes. This disclosure is significant as it reflects ResMed’s commitment to corporate governance and ethical sourcing, potentially impacting its reputation and stakeholder trust.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
ResMed Inc. has reported a change in beneficial ownership, with Chief Financial Officer Brett Sandercock executing a transaction involving the sale of 3,644 shares of ResMed common stock at a price of $244.59 per share. This transaction was conducted under a pre-established Rule 10b5-1 plan, highlighting a strategic financial decision within the company’s management. The transaction reflects ongoing management activities and may influence stakeholder perceptions regarding the company’s financial strategies.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$33.70 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
Resmed Inc has announced an update regarding the foreign exchange rate for its upcoming dividend distribution to holders of CHESS Depositary Interests (CDIs) trading on the Australian Securities Exchange. The exchange rate has been set at 0.6400 U.S. dollars for 1.00 Australian dollar, resulting in a dividend of 0.0828 Australian dollars per CDI. The announcement also highlights the potential reduction in the default U.S. withholding tax from 30% to 15% for Australian residents, contingent upon the submission of the appropriate tax forms. This update may impact the financial returns for CDI holders and reflects Resmed’s ongoing commitment to transparent communication with its stakeholders.
ResMed Inc has announced a net decrease in the number of CHESS Depositary Interests (CDIs) issued over quoted securities for April 2025, with a reduction of 9,500,350 CDIs compared to the previous month. This change is attributed to net transfers of securities between CDIs and common stock on the NYSE. Additionally, there has been an increase in other securities due to stock options, restricted stock units, employee stock purchase plans, and share repurchases on the NYSE, reflecting the company’s ongoing financial and operational adjustments.